Please use this identifier to cite or link to this item:
Title: First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
Austin Authors: Whittle, James R;Lickliter, Jason D;Gan, Hui K ;Scott, Andrew M ;Simes, John;Solomon, Benjamin J;MacDiarmid, Jennifer A;Brahmbhatt, Himanshu;Rosenthal, Mark A
Affiliation: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Monash Cancer Centre, East Bentleigh, Victoria, Australia
Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia
EnGeneIC Ltd, Lane Cove West, NSW, Australia
Issue Date: Dec-2015
Date: 2015-08-13
Publication information: Journal of Clinical Neuroscience 2015; 22(12): 1889-94
Abstract: There are limited treatment options for patients with recurrent glioblastoma (GBM). The EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages theoretically effective concentrations of chemotherapeutic drugs that are designed to target tumors via minicell-surface attached bispecific proteins (EnGeneIC, Lane Cove West, NSW, Australia). Epidermal growth factor receptor (EGFR) is overexpressed in 40-50% of patients with GBM and is a promising target for new therapeutics. (V)EDVDox contains doxorubicin (Dox) within the minicells and targets EGFR through Vectibix (V; Amgen Biologicals, Thousand Oaks, CA, USA). We conducted a first in human Phase I study of (V)EDVDox in adults with recurrent GBM expressing EGFR on immunohistochemistry, following standard therapy including radiation and temozolomide, to establish a safe maximum tolerated dose and determine a recommended Phase II dose (RPTD). (V)EDVDox was administered weekly in an 8week cycle, with dose escalation in successive cohorts of patients using a standard 3+3 design. In total, 14 patients were treated at three dose levels, and the RPTD was identified as 5×10(9)(V)EDVDox. Overall (V)EDVDox was well tolerated, with no dose limiting toxicity and no withdrawals from the study due to adverse events. The most common adverse events were nausea, fever, and chills or rigors, experienced in seven, five and five patients, respectively. Transient uncomplicated hypophosphatemia was seen in seven patients and was not dose-related. Our results demonstrate that (V)EDVDox, up to a dose of 5×10(9)(V)EDVDox weekly, is well tolerated in patients with recurrent GBM.
DOI: 10.1016/j.jocn.2015.06.005
ORCID: 0000-0002-6656-295X
Journal: Journal of Clinical Neuroscience
PubMed URL: 26279503
Type: Journal Article
Subjects: Doxorubicin
Epidermal growth factor receptor
First in human
Phase I trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 14, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.